Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice

• Egile Nagusiak: Melinda J. Gooderham (Egilea), Andrew E. Pink (Egilea), Eric L. Simpson (Egilea), Jonathan I. Silverberg (Egilea), Erman Güler (Egilea), Melissa Watkins (Egilea)
• Formatua: Liburua
• Argitaratua: Adis, Springer Healthcare, 2023-07-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Abrocitinib is a Janus kinase (JAK) 1-selective inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). Although specific dose recommendations for abrocitinib vary across regional product labels, abrocitinib 100 mg once daily is recommended as a starting and maint...